{
  "id": "a1cce0d7a534489c",
  "title": "2 Minute Medicine : Pharma Roundup \u2013 New oral gonorrhea antibiotic Nuzolvence ( zoliflodacin ), late \u2011 December cardiovascular and oncology drug approvals , first targeted complement inhibitor therapy for HSCT \u2011 TMA ( Yartemlea ), and antibody \u2011 drug...",
  "description": "20260113T020000Z",
  "content": "",
  "source": "2minutemedicine.com",
  "source_url": "https://www.2minutemedicine.com/2-minute-medicine-pharma-roundup-new-oral-gonorrhea-antibiotic-nuzolvence-zoliflodacin-late%E2%80%91december-cardiovascular-and-oncology-drug-approvals-first-targeted-complement-inhibit/",
  "published_at": "20260113T020000Z",
  "fetched_at": "2026-01-14T00:24:05.619157+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "antibiotic",
    "drug"
  ],
  "location": "United States",
  "raw_data": {
    "url": "https://www.2minutemedicine.com/2-minute-medicine-pharma-roundup-new-oral-gonorrhea-antibiotic-nuzolvence-zoliflodacin-late%E2%80%91december-cardiovascular-and-oncology-drug-approvals-first-targeted-complement-inhibit/",
    "url_mobile": "https://www.2minutemedicine.com/2-minute-medicine-pharma-roundup-new-oral-gonorrhea-antibiotic-nuzolvence-zoliflodacin-late%e2%80%91december-cardiovascular-and-oncology-drug-approvals-first-targeted-complement-inhibit/?amp_markup=1",
    "title": "2 Minute Medicine : Pharma Roundup \u2013 New oral gonorrhea antibiotic Nuzolvence ( zoliflodacin ), late \u2011 December cardiovascular and oncology drug approvals , first targeted complement inhibitor therapy for HSCT \u2011 TMA ( Yartemlea ), and antibody \u2011 drug...",
    "seendate": "20260113T020000Z",
    "socialimage": "https://www.2minutemedicine.com/wp-content/uploads/2025/05/ChatGPT-Image-May-12-2025-at-10_22_23-AM.png",
    "domain": "2minutemedicine.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}